Early Registration Savings Offer Expires In:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Johan RockbergProfessor at KTH Royal Institute of TechnologySpeaker
Profile
Professor in directed evolution and antibody technology at KTH Royal Inst. Technology, Sweden. Director of GeneNova, a center focused on developing platforms for more cost effective, safe and efficacious AAV based gene therapy through interdisciplinary industry and academia collaborations. He is an expert in protein and cell line engineering with 19000 citations and 55+ publications. Co-PI of human protein atlas program cataloging all human proteins. Co-founder five of companies including StrikePharma AB (Uppsala) developing cancer vaccine, Abclon (Seoul, SouthKorea) developing CAR-T and immunotherapy. Elected member of the Swedish Young Academy (SUA) and Royal Academy of Science (KVA) research policy committee.
Agenda Sessions
Cellular demands of secreted biopharmaceuticals and AAV– how systems and synthetic biology improve quality and titer
, 9:00amView Session